Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our Orexin Receptor 2 Agonist Program to bring potentially transformative treatment options to patients with sleep-wake disorders.
Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing SerpinPC as a potential novel subcutaneous treatment for hemophilia B patients with potential expansion into other bleeding disorders.
Patient-Centric Mission.
Asset-Centric Approach.
We’re pursuing our LockBody® Technology Platform with the aim to redefine immuno-oncology treatment for patients with cancer.
We are leaders, innovators, and scientists aiming to pursue medicines that are transformational for patients.
Latest News
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares